1
|
Ancillary Techniques to Relieve the Pain Associated With Botulinum Injections for Palmar and Plantar Hyperhidrosis. Dermatol Surg 2022; 48:699-700. [PMID: 35353754 DOI: 10.1097/dss.0000000000003441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Kelly A, Gandhi R, Natkunarajah J. 'Your mascara is running'. Clin Exp Dermatol 2021; 47:639-641. [PMID: 34962316 DOI: 10.1111/ced.15015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 11/09/2021] [Accepted: 11/10/2021] [Indexed: 11/28/2022]
Abstract
Chromhidrosis is a rare disorder, which can have significant psychosocial consequences for patients, particularly when it affects the face, as it can be mistaken for scarring, dirt or erroneous make-up application. Chromhidrosis can be divided into apocrine, eccrine and pseudo subtypes. We present a case of apocrine chromhidrosis localized to the bilateral cheek area.
Collapse
Affiliation(s)
- A Kelly
- Department of Dermatology, Kingston Hospital, Kingston Hospital NHS Foundation Trust, Kingston upon Thames, Surrey, UK
| | - R Gandhi
- Department of Dermatology, Kingston Hospital, Kingston Hospital NHS Foundation Trust, Kingston upon Thames, Surrey, UK
| | - J Natkunarajah
- Department of Dermatology, Kingston Hospital, Kingston Hospital NHS Foundation Trust, Kingston upon Thames, Surrey, UK
| |
Collapse
|
3
|
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins (Basel) 2021; 13:toxins13020120. [PMID: 33562846 PMCID: PMC7915854 DOI: 10.3390/toxins13020120] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 01/19/2021] [Accepted: 01/22/2021] [Indexed: 12/21/2022] Open
Abstract
Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.
Collapse
|
4
|
Abstract
Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions. This review aims to analyze published literature regarding the benefits and risks of the off-label use of BoNTA beyond facial lines, including eccrine hidrocystomas, enlarged pores, keloids and hypertrophic scars, hidradenitis suppurativa, hyperhidrosis, masseter muscle hypertrophy, and salivary gland hypertrophy, among others. A MEDLINE search from January 2000 to December 2019 was conducted on the off-label uses of botulinum toxin in dermatology.
Collapse
Affiliation(s)
- Tina S Alster
- Washington Institute of Dermatologic Laser Surgery, 1430 K St NW, Suite 200, Washington, DC, 20005, USA.
| | - Iris S Harrison
- Washington Institute of Dermatologic Laser Surgery, 1430 K St NW, Suite 200, Washington, DC, 20005, USA
| |
Collapse
|
5
|
Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies. J Am Acad Dermatol 2017; 76:1027-1042. [PMID: 28522039 DOI: 10.1016/j.jaad.2016.11.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 11/03/2016] [Accepted: 11/06/2016] [Indexed: 12/27/2022]
Abstract
The use of neuromodulators for therapeutic and cosmetic indications has proven to be remarkably safe. While aesthetic and functional adverse events are uncommon, each anatomic region has its own set of risks of which the physician and patient must be aware before treatment. The therapeutic usages of botulinum toxins now include multiple specialties and multiple indications. New aesthetic indications have also developed, and there has been an increased utilization of combination therapies to combat the effects of global aging. In the second article in this continuing medical education series, we review the prevention and treatment of adverse events, therapeutic and novel aesthetic indications, controversies, and a brief overview of combination therapies.
Collapse
Affiliation(s)
| | - Seth L Matarasso
- Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, California
| | - David M Ozog
- Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
| |
Collapse
|
6
|
Affiliation(s)
- Jason E. Sammons
- Department of Clinical Medicine, Avalon University School of Medicine, Willemstad, CW, USA
| | | |
Collapse
|
7
|
Campanati A, Martina E, Giuliodori K, Consales V, Bobyr I, Offidani A. Botulinum Toxin Off-Label Use in Dermatology: A Review. Skin Appendage Disord 2017; 3:39-56. [PMID: 28612001 DOI: 10.1159/000452341] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 10/05/2016] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis. It is currently used for aesthetic treatments and in the focal hyperhidrosis. Recently, botulinum toxin has also been used experimentally in many other dermatological conditions with good results. OBJECTIVE To review and analyze the possible botulinum toxin off-label applications published. METHODS A retrospective review of the published data was conducted. CONCLUSIONS this potent drug can lead to several off-label indications of interest for dermatologists. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and dose protocols.
Collapse
Affiliation(s)
- Anna Campanati
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| | - Emanuela Martina
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| | - Katia Giuliodori
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| | - Veronica Consales
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| | - Ivan Bobyr
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
8
|
Nair PA, Kota RKS, Surti NK, Diwan NG, Gandhi SS. Yellow pseudochromhidrosis in a young female. Indian Dermatol Online J 2017; 8:42-44. [PMID: 28217472 PMCID: PMC5297270 DOI: 10.4103/2229-5178.198778] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Chromhidrosis is a rare disorder in which there is pigmentation of sweat in a variety of colors. It can be classified into apocrine, pseudoeccrine, and true eccrine chromhidrosis. Pseudochromhidrosis is a condition in which the excreted sweat is colorless, but later acquires color due to contact with chromogenic chemicals. Systemic and topical antibiotics are the mainstay of treatment. Although it does not constitute a major health issue, it causes psychological stress and social embarrassment. A 20-year-old female presented to us with yellow-colored sweat and discoloration of clothes since 1 month. Routine laboratory investigations were normal. Skin scrapings were negative for fungus and bacteria. Skin biopsy was also normal. She was labelled as a case of pseudochromhidrosis, and oral and topical antibiotics were prescribed, to which she responded well.
Collapse
Affiliation(s)
- Pragya A Nair
- Department of Skin and VD, Shree Krishna Hospital, Anand, Gujarat, India
| | | | - Nishit K Surti
- Department of Skin and VD, Shree Krishna Hospital, Anand, Gujarat, India
| | - Nilofar G Diwan
- Department of Skin and VD, Shree Krishna Hospital, Anand, Gujarat, India
| | - Shailee S Gandhi
- Department of Skin and VD, Shree Krishna Hospital, Anand, Gujarat, India
| |
Collapse
|
9
|
Forbat E, Ali F, Al-Niaimi F. Non-cosmetic dermatological uses of botulinum neurotoxin. J Eur Acad Dermatol Venereol 2016; 30:2023-2029. [DOI: 10.1111/jdv.13772] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 04/19/2016] [Indexed: 12/29/2022]
Affiliation(s)
| | - F.R. Ali
- Dermatological Surgery & Laser Unit; St John's Institute of Dermatology; St Thomas' Hospital; London UK
| | - F. Al-Niaimi
- Dermatological Surgery & Laser Unit; St John's Institute of Dermatology; St Thomas' Hospital; London UK
| |
Collapse
|
10
|
Semkova K, Gergovska M, Kazandjieva J, Tsankov N. Hyperhidrosis, bromhidrosis, and chromhidrosis: Fold (intertriginous) dermatoses. Clin Dermatol 2015; 33:483-91. [DOI: 10.1016/j.clindermatol.2015.04.013] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Gaffney DC, Cooper HL. Coloured sweat in two brothers: First report of familial chromhidrosis. Australas J Dermatol 2015; 57:e23-5. [DOI: 10.1111/ajd.12262] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Accepted: 09/10/2014] [Indexed: 11/26/2022]
Affiliation(s)
- Daniel C Gaffney
- Department of Dermatology; St. Mary's Hospital; Portsmouth Hospitals NHS Trust; Portsmouth UK
| | - Hywel L Cooper
- Department of Dermatology; St. Mary's Hospital; Portsmouth Hospitals NHS Trust; Portsmouth UK
| |
Collapse
|
12
|
Xiao XM, Xu HX, Li CR, Wang BX. Unilateral chromhidrosis versus unilateral pseudochromhidrosis: an interesting phenomenon. Clin Exp Dermatol 2015; 40:572-4. [DOI: 10.1111/ced.12555] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2014] [Indexed: 11/29/2022]
Affiliation(s)
- X.-M. Xiao
- Institute of Dermatology; Chinese Academy of Medical Sciences; 12 Jiangwangmiao Street Nanjing Jiangsu 210042 China
| | - H.-X. Xu
- Institute of Dermatology; Chinese Academy of Medical Sciences; 12 Jiangwangmiao Street Nanjing Jiangsu 210042 China
| | - C.-R. Li
- Institute of Dermatology; Chinese Academy of Medical Sciences; 12 Jiangwangmiao Street Nanjing Jiangsu 210042 China
| | - B.-X. Wang
- Institute of Dermatology; Chinese Academy of Medical Sciences; 12 Jiangwangmiao Street Nanjing Jiangsu 210042 China
| |
Collapse
|
13
|
Al-Ghamdi AS, Alghanemy N, Joharji H, Al-Qahtani D, Alghamdi H. Botulinum toxin: Non cosmetic and off-label dermatological uses. JOURNAL OF DERMATOLOGY & DERMATOLOGIC SURGERY 2015. [DOI: 10.1016/j.jdds.2014.06.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
|
15
|
Beer K, Oakley H. Axillary chromhidrosis: report of a case, review of the literature and treatment considerations. J Cosmet Dermatol 2010; 9:318-20. [DOI: 10.1111/j.1473-2165.2010.00530.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
|
17
|
Abstract
Since its introduction into clinical medicine in 1980, botulinum toxin has become a major therapeutic drug with applications valuable to many medical sub-specialties. Its use was spearheaded in ophthalmology where its potential applications have expanded to cover a broad range of visually related disorders. These include dystonic movement disorders, strabismus, nystagmus, headache syndromes such as migraine, lacrimal hypersecretion syndromes, eyelid retraction, spastic entropion, compressive optic neuropathy, and, more recently, periorbital aesthetic uses. Botulinum toxin is a potent neurotoxin that blocks the release of acetylcholine at the neuromuscular junction of cholinergic nerves. When used appropriately it will weaken the force of muscular contraction, or inhibit glandular secretion. Recovery occurs over 3 to 4 months from nerve terminal sprouting and regeneration of inactivated proteins necessary for degranualtion of acetylcholine vesicles. Complications are related to chemodenervation of adjacent muscle groups, injection technique, and immunological mechanisms.
Collapse
Affiliation(s)
- Jonathan J Dutton
- Department of Ophthalmology, University of North Carolina, Chapel Hill, NC 27599-7040, USA
| | | |
Collapse
|
18
|
Truong DD, Jost WH. Botulinum toxin: Clinical use. Parkinsonism Relat Disord 2006; 12:331-55. [PMID: 16870487 DOI: 10.1016/j.parkreldis.2006.06.002] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2006] [Revised: 06/21/2006] [Accepted: 06/21/2006] [Indexed: 01/25/2023]
Abstract
Since its development for the use of blepharospasm and strabismus more than 2.5 decades ago, botulinum neurotoxin (BoNT) has become a versatile drug in various fields of medicine. It is the standard of care in different disorders such as cervical dystonia, hemifacial spasm, focal spasticity, hyperhidrosis, ophthalmological and otolaryngeal disorders. It has also found widespread use in cosmetic applications. Many other indications are currently under investigation, including gastroenterologic and urologic indications, analgesic management and migraine. This paper is an extensive review of the spectrum of BoNT clinical applications.
Collapse
Affiliation(s)
- Daniel D Truong
- The Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA.
| | | |
Collapse
|
19
|
|